FeesSafety
Pluang+

Southwest Gas reports strong Q3 earnings, regulatory wins, and on-track Great Basin 2028 expansion.

Company Fundamentals
04 Nov 2026, 15:00 WIB
PRNewsWire
View Source
Bullish
Southwest Gas reports strong Q3 earnings, regulatory wins, and on-track Great Basin 2028 expansion.

Southwest Gas Holdings announced strong third-quarter 2026 results, driven by regulatory approvals in Nevada and California that increased annual revenues by $80 million. The company is progressing with its Arizona rate case and expects new rates in April 2027. Its Great Basin 2028 expansion project remains on schedule for a late 2028 service start, supported by binding customer agreements and a $2.3 billion investment. These developments position Southwest Gas for sustainable growth and operational excellence.

Southwest Gas Holdings' third-quarter 2026 results provide context for readers following utilities. For readers following utilities, here is Pluang's market snapshot as of Nov 04, 2026 19:03 WIB: Of 39 priced Utilities-sector US stocks tradable on Pluang, 16 rose and 17 fell today. Dominion Energy Inc (D) was priced at USD 67.40 with a 1-day change of +0.93% and 100% sell order activity. Ameren Corporation (AEE) was at USD 111.35, up 0.89%, and American Electric Power Company (AEP) was at USD 131.00, up 0.88% with 82% buy order activity and a typical hold time of 70 days.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
37 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
37 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
37 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
37 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
37 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App